Background Development of in vivo biomarkers has shifted the diagnosis of Alzheimer's
disease (AD) from the later dementia stages of disease towards the earlier stages and has …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a major
contributor to dementia cases worldwide. AD is clinically characterized by learning, memory …

Synapse dysfunction and loss are hallmarks of neurodegenerative diseases that correlate
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …

In Alzheimer's disease, amyloid-beta (Aβ) triggers the trans-synaptic spread of tau
pathology, and aberrant synaptic activity has been shown to promote tau spreading. Aβ …

Objective Increased presynaptic dysfunction measured by cerebrospinal fluid (CSF) growth‐
associated protein‐43 (GAP43) may be observed in Alzheimer's disease (AD), but how CSF …

Alzheimer's disease (AD) is currently constrained by limited clinical treatment options. The
initial pathophysiological event, which can be traced back to decades before the clinical …

Since the establishment of the biomarker-based ATN (Amyloid/Tau/Neurodegeneration)
framework in Alzheimer's disease (AD), the diagnosis of AD has become more precise, and …

Background Synaptic dysfunction and degeneration are central to Alzheimer's disease (AD)
and have been found to correlate strongly with cognitive decline. Thus, studying …

Early cognitive decline in patients with Alzheimer's (AD) is associated with quantifiable
structural and functional connectivity changes in the brain. AD dysregulation of Aβ and tau …

Background Synaptic dysfunction is an early core feature of Alzheimer's disease (AD),
closely associated with cognitive symptoms. Neuregulin 1 (NRG1) is a growth and …